Methylnaltrexone (Relistor): clinical updates from two independent sources

Methylnaltrexone (Relistor) is a peripherally-acting μ-opioid antagonist used for the treatment of opioid induced constipation. Two independent organizations have recently published updated clinical information on this drug: Australian Prescriber. New drugs: Methylnaltrexone Health Canada. Summary Basis of Decision (SBD) RELISTOR The Scottish Medicines Consortium also reviewed Relistor in January 2009.

Methylnaltrexone (Relistor) for opioid induced constipation: SMC review

The Scottish Medicines Consortium issued on 8th December, 2008 an advice on the recently approved opioid antagonist methylnaltrexone ADVICE: following a full submissionMethylnaltrexone  (Relistor)  is  accepted  for  restricted  use  within  NHS  Scotland  for treatment  of  opioid-induced  constipation  in  advanced  illness  patients  who  are  receiving palliative care when response to usual laxative therapy has not been […]

Are you a visual learner interested in learning psychopharmacology? Click here to get our videos